• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Depression in Parkinsons Disease Has Both Psychological and Pathological Causes

Posted on: Thursday, 31 August 2006, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c41448) has announced the addition of the new Datamonitor report "Pipeline Insight: Parkinsons Disease And Restless Legs Syndrome - Reformulations Set To Drive Near-Term Growth" to their offering.

Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinsons disease or Restless Legs Syndrome. Although available treatments are effective, numerous unmet needs prevail. Several compounds are in late-stage development and are forecast to achieve sales of $519m for Parkinsons disease and $399m for Restless Legs Syndrome in 2015.

Scope of this title:

-Analysis of patient potential, unmet needs and clinical trial design in Parkinsons disease and Restless Legs Syndrome across the US, EU and Japan

-Overview of drugs in pre-registration, Phase III, II, I and preclinical development; with analysis of key companies involved in the market

-Detailed profiles of key compounds in development for Parkinsons disease and Restless Legs Syndrome, with forecasts of drug revenues to 2015

-Discussion of innovative early stage products and insight from key industry opinion leaders

Highlights of this title:

Dopamine agonists with alternative delivery systems are expected to drive near-term changes in the Parkinsons disease market. While Schwarzs rotigotine patch holds several advantages over current oral treatments its success looks set to be eclipsed by GSKs once-daily tablet, Requip Modutab, which is forecast to reach peak sales of $543m in 2011.

The mid-stage pipeline for Parkinsons disease is unimpressive, with a host of potential neuroprotectants failing to demonstrate conclusive benefits in slowing disease progression. The most exciting near-term prospects are likely to come from cell and gene therapy products such as Titan/Scherings Spheramine or Avigens AV-201.

The recent approval of the dopamine agonists Requip and Mirapex for Restless Legs Syndrome have provided a viable treatment option. However, unmet needs still exist and treatments, such as XenoPorts XP13512 which offer alternative mechanisms to dopaminergic stimulation may provide greater symptomatic benefit to current treatments.

Reasons to order your copy:

-Understand unmet needs in the Parkinsons disease and Restless Legs Syndrome market based on key opinion leader comments

-Benchmark key late-stage Parkinsons disease and Restless Legs Syndrome compounds against current market leaders

-Assess the global sales forecasts of late-stage pipeline drugs; and examine their clinical and commercial potential

Key Topics Covered Include:

- Executive summary

- Scope of the analysis

- Patient potential- parkinsons disease

- Parkinsons disease r&d approach

- Parkinsons disease pipeline analysis

- Dopaminergics- late-stage drug analysis and forecasts

- Dopamine agonists- late-stage drug analysis and forecasts

- Adenosine a2a receptor antagonists- late-stage drug analysis and forecasts

- Neuroprotectants- late stage drug analysis

- Cell/gene therapy- late stage product analysis

- Others- late-stage drug analysis and forecasts

- Restless legs syndrome

For more information visit http://www.researchandmarkets.com/reports/c41448

Source: Datamonitor

Source: Business Wire

More News in this Category